Characteristics and outcomes of patients with mWT1 stratified by single WT1 or mhWT1
| Variable . | mhWT1 . | P value . | |
|---|---|---|---|
| No . | Yes . | ||
| (n = 20) . | (n = 13) . | ||
| Age at diagnosis, y | |||
| Median (min, max) | 46.8 (18.4, 67.5) | 42.7 (26.7, 71.8) | .85 |
| Age at alloSCT, y | |||
| Median (min, max) | 48.0 (18.7, 68.0) | 44.1 (27.5, 72.2) | .8 |
| Sex | |||
| Female | 9 (45.0%) | 3 (23.1%) | .36 |
| Male | 11 (55.0%) | 10 (76.9%) | |
| Ethnicity | |||
| Caucasian | 17 (85.0%) | 11 (84.6%) | 1 |
| Other | 3 (15.0%) | 2 (15.4%) | |
| WT1 first detected | |||
| Initial diagnosis | 14 (70.0%) | 7 (53.8%) | .57 |
| Relapse | 6 (30.0%) | 6 (46.2%) | |
| Disease characteristics | |||
| Disease | |||
| AML | 15 (75%) | 10 (76.9%) | .39 |
| MDS | 1 (5%) | 2 (15.4%) | |
| MPAL | 1 (5%) | 1 (7.7%) | |
| Others | 3 (15%) | 0 (0%) | |
| Hemoglobin ≥ 10 g/dL at diagnosis | |||
| No | 17 (85.0%) | 11 (84.6%) | 1 |
| Yes | 2 (10.0%) | 1 (7.7%) | |
| Missing | 1 (5.0%) | 1 (7.7%) | |
| Platelets ≥ 100 × 103/μL at diagnosis | |||
| No | 12 (60.0%) | 10 (76.9%) | .42 |
| Yes | 7 (35.0%) | 2 (15.4%) | |
| Missing | 1 (5.0%) | 1 (7.7%) | |
| Abnormal karyotype at diagnosis | |||
| No | 8 (40.0%) | 8 (61.5%) | .47 |
| Yes | 11 (55.0%) | 5 (38.5%) | |
| Missing | 1 (5.0%) | 0 (0%) | |
| Monosomy 7 at diagnosis | |||
| No | 18 (90.0%) | 13 (100%) | 1 |
| Yes | 1 (5.0%) | 0 (0%) | |
| Missing | 1 (5.0%) | 0 (0%) | |
| Complex karyotype at diagnosis | |||
| No | 16 (80.0%) | 13 (100%) | .38 |
| Yes | 3 (15.0%) | 0 (0%) | |
| Missing | 1 (5.0%) | 0 (0%) | |
| Monosomal karyotype at diagnosis | |||
| No | 18 (90.0%) | 13 (100%) | 1 |
| Yes | 1 (5.0%) | 0 (0%) | |
| Missing | 1 (5.0%) | 0 (0%) | |
| maxWT1 VAF | |||
| Median [min, max] | 34.5 [4.00, 84.0] | 33.0 [12.0, 49.0] | .66 |
| Isolated WT1 (no comutation) | |||
| No | 15 (75.0%) | 13 (100%) | .14 |
| Yes | 5 (25.0%) | 0 (0%) | |
| mWT1 in codons 301-303 | |||
| No | 19 (95.0%) | 7 (53.8%) | .02 |
| Yes | 1 (5.0%) | 6 (46.2%) | |
| mWT1 in codons 312-314 | |||
| No | 14 (70.0%) | 5 (38.5%) | .15 |
| Yes | 6 (30.0%) | 8 (61.5%) | |
| mWT1 in zinc-finger motif | |||
| No | 17 (85.0%) | 11 (84.6%) | 1 |
| Yes | 3 (15.0%) | 2 (15.4%) | |
| CR/CRi at alloSCT | |||
| No | 2 (10.0%) | 3 (23.1%) | .64 |
| Yes | 17 (85.0%) | 10 (76.9%) | |
| Missing | 1 (5.0%) | 0 (0%) | |
| DRI | |||
| Low | 3 (15%) | 1 (7.7%) | .83 |
| Intermediate | 13 (65%) | 9 (69.2%) | |
| High | 3 (15%) | 2 (15.4%) | |
| NA | 1 (5%) | 1 (7.7%) | |
| Comutations | |||
| ASXL1 | |||
| No | 17 (85.0%) | 13 (100%) | .40 |
| Yes | 3 (15.0%) | 0 (0%) | |
| BCOR | |||
| No | 19 (95.0%) | 13 (100%) | 1 |
| Yes | 1 (5.0%) | 0 (0%) | |
| CEBPA | |||
| No | 17 (85.0%) | 9 (69.2%) | .52 |
| Yes | 3 (15.0%) | 4 (30.8%) | |
| CSF3R | |||
| No | 19 (95.0%) | 12 (92.3%) | 1 |
| Yes | 1 (5.0%) | 1 (7.7%) | |
| DNMT3A | |||
| No | 19 (95.0%) | 10 (76.9%) | .31 |
| Yes | 1 (5.0%) | 3 (23.1%) | |
| FLT3 | |||
| No | 14 (70.0%) | 4 (30.8%) | .06 |
| Yes | 6 (30.0%) | 9 (69.2%) | |
| IDH1 | |||
| No | 19 (95.0%) | 12 (92.3%) | 1 |
| Yes | 1 (5.0%) | 1 (7.7%) | |
| IDH2 | |||
| No | 19 (95.0%) | 13 (100%) | 1 |
| Yes | 1 (5.0%) | 0 (0%) | |
| GATA2 | |||
| No | 19 (95.0%) | 12 (92.3%) | 1 |
| Yes | 1 (5.0%) | 1 (7.7%) | |
| JAK2 | |||
| No | 19 (95.0%) | 12 (92.3%) | 1 |
| Yes | 1 (5.0%) | 1 (7.7%) | |
| KRAS | |||
| No | 19 (95.0%) | 13 (100%) | 1 |
| Yes | 1 (5.0%) | 0 (0%) | |
| NPM1 | |||
| No | 18 (90.0%) | 11 (84.6%) | 1 |
| Yes | 2 (10.0%) | 2 (15.4%) | |
| NRAS | |||
| No | 17 (85.0%) | 12 (92.3%) | .93 |
| Yes | 3 (15.0%) | 1 (7.7%) | |
| PHF6 | |||
| No | 19 (95.0%) | 13 (100%) | 1 |
| Yes | 1 (5.0%) | 0 (0%) | |
| PTPN11 | |||
| No | 19 (95.0%) | 11 (84.6%) | .69 |
| Yes | 1 (5.0%) | 2 (15.4%) | |
| RUNX1 | |||
| No | 18 (90.0%) | 9 (69.2%) | .29 |
| Yes | 2 (10.0%) | 4 (30.8%) | |
| SF3B1 | |||
| No | 20 (100%) | 11 (84.6%) | .29 |
| Yes | 0 (0%) | 2 (15.4%) | |
| SRSF2 | |||
| No | 19 (95.0%) | 13 (100%) | 1 |
| Yes | 1 (5.0%) | 0 (0%) | |
| TET2 | |||
| No | 18 (90.0%) | 12 (92.3%) | 1 |
| Yes | 2 (10.0%) | 1 (7.7%) | |
| TP53 | |||
| No | 19 (95.0%) | 13 (100%) | 1 |
| Yes | 1 (5.0%) | 0 (0%) | |
| ZRSR2 | |||
| No | 19 (95.0%) | 13 (100%) | 1 |
| Yes | 1 (5.0%) | 0 (0%) | |
| Transplantation characteristics and outcomes | |||
| HCT-CI ≥ 3 | |||
| No | 11 (55.0%) | 9 (69.2%) | .65 |
| Yes | 9 (45.0%) | 4 (30.8%) | |
| Conditioning intensity | |||
| Myeloablative | 12 (60.0%) | 8 (61.5%) | 1 |
| Reduced intensity | 7 (35.0%) | 5 (38.5%) | |
| Missing | 1 (5.0%) | 0 (0%) | |
| Conditioning | |||
| Bu/Cy | 4 (20.0%) | 1 (7.7%) | NA |
| Bu/Flu | 4 (20.0%) | 3 (23.1%) | |
| Bu/Flu/ATG | 1 (5.0%) | 0 (0%) | |
| Cy/Flu/thiotepa/TLI | 2 (10.0%) | 0 (0%) | |
| Cy/TBI | 2 (10.0%) | 2 (15.4%) | |
| Flu/Mel | 4 (20.0%) | 4 (30.8%) | |
| Flu/TBI | 2 (10.0%) | 1 (7.7%) | |
| Bu/Cy/ATG | 0 (0%) | 1 (7.7%) | |
| Flu/BCNU/Mel | 1 (5%) | 1 (7.7%) | |
| Graft source | |||
| Peripheral blood | 18 (90.0%) | 13 (100%) | 1 |
| Bone marrow | 1 (5.0%) | 0 (0%) | |
| Missing | 1 (5.0%) | 0 (0%) | |
| Donor type | |||
| MRD | 5 (25.0%) | 1 (7.7%) | .36 |
| MUD | 11 (55.0%) | 9 (69.2%) | |
| MMUD | 0 (0%) | 1 (7.7%) | |
| Haploidentical | 4 (20.0%) | 2 (15.4%) | |
| Major/bidirectional ABO mismatch | |||
| No | 15 (75.0%) | 10 (76.9%) | 1 |
| Yes | 4 (20.0%) | 3 (23.1%) | |
| Missing | 1 (5.0%) | 0 (0%) | |
| GVHD prophylaxis | |||
| CD34 selection | 1 (5.0%) | 0 (0%) | .16 |
| Tacrolimus + methotrexate (± ATG) | 13 (65%) | 9 (69.3%) | |
| Cyclosporine + methotrexate | 2 (10.0%) | 1 (7.7%) | |
| Tacrolimus + mycophenolate | 3 (15.0%) | 0 (0%) | |
| PT-Cy based | 0 (0%) | 3 (23.1%) | |
| None | 1 (5.0%) | 0 (0%) | |
| Grade 2-4 acute GVHD | |||
| No | 17 (85.0%) | 10 (76.9%) | .9 |
| Yes | 3 (15.0%) | 3 (23.1%) | |
| Grade 3-4 acute GVHD | |||
| No | 13 (65.0%) | 12 (92.3%) | .17 |
| Yes | 7 (35.0%) | 1 (7.7%) | |
| Moderate/severe chronic GVHD | |||
| No | 18 (90.0%) | 11 (84.6%) | 1 |
| Yes | 2 (10.0%) | 2 (15.4%) | |
| Variable . | mhWT1 . | P value . | |
|---|---|---|---|
| No . | Yes . | ||
| (n = 20) . | (n = 13) . | ||
| Age at diagnosis, y | |||
| Median (min, max) | 46.8 (18.4, 67.5) | 42.7 (26.7, 71.8) | .85 |
| Age at alloSCT, y | |||
| Median (min, max) | 48.0 (18.7, 68.0) | 44.1 (27.5, 72.2) | .8 |
| Sex | |||
| Female | 9 (45.0%) | 3 (23.1%) | .36 |
| Male | 11 (55.0%) | 10 (76.9%) | |
| Ethnicity | |||
| Caucasian | 17 (85.0%) | 11 (84.6%) | 1 |
| Other | 3 (15.0%) | 2 (15.4%) | |
| WT1 first detected | |||
| Initial diagnosis | 14 (70.0%) | 7 (53.8%) | .57 |
| Relapse | 6 (30.0%) | 6 (46.2%) | |
| Disease characteristics | |||
| Disease | |||
| AML | 15 (75%) | 10 (76.9%) | .39 |
| MDS | 1 (5%) | 2 (15.4%) | |
| MPAL | 1 (5%) | 1 (7.7%) | |
| Others | 3 (15%) | 0 (0%) | |
| Hemoglobin ≥ 10 g/dL at diagnosis | |||
| No | 17 (85.0%) | 11 (84.6%) | 1 |
| Yes | 2 (10.0%) | 1 (7.7%) | |
| Missing | 1 (5.0%) | 1 (7.7%) | |
| Platelets ≥ 100 × 103/μL at diagnosis | |||
| No | 12 (60.0%) | 10 (76.9%) | .42 |
| Yes | 7 (35.0%) | 2 (15.4%) | |
| Missing | 1 (5.0%) | 1 (7.7%) | |
| Abnormal karyotype at diagnosis | |||
| No | 8 (40.0%) | 8 (61.5%) | .47 |
| Yes | 11 (55.0%) | 5 (38.5%) | |
| Missing | 1 (5.0%) | 0 (0%) | |
| Monosomy 7 at diagnosis | |||
| No | 18 (90.0%) | 13 (100%) | 1 |
| Yes | 1 (5.0%) | 0 (0%) | |
| Missing | 1 (5.0%) | 0 (0%) | |
| Complex karyotype at diagnosis | |||
| No | 16 (80.0%) | 13 (100%) | .38 |
| Yes | 3 (15.0%) | 0 (0%) | |
| Missing | 1 (5.0%) | 0 (0%) | |
| Monosomal karyotype at diagnosis | |||
| No | 18 (90.0%) | 13 (100%) | 1 |
| Yes | 1 (5.0%) | 0 (0%) | |
| Missing | 1 (5.0%) | 0 (0%) | |
| maxWT1 VAF | |||
| Median [min, max] | 34.5 [4.00, 84.0] | 33.0 [12.0, 49.0] | .66 |
| Isolated WT1 (no comutation) | |||
| No | 15 (75.0%) | 13 (100%) | .14 |
| Yes | 5 (25.0%) | 0 (0%) | |
| mWT1 in codons 301-303 | |||
| No | 19 (95.0%) | 7 (53.8%) | .02 |
| Yes | 1 (5.0%) | 6 (46.2%) | |
| mWT1 in codons 312-314 | |||
| No | 14 (70.0%) | 5 (38.5%) | .15 |
| Yes | 6 (30.0%) | 8 (61.5%) | |
| mWT1 in zinc-finger motif | |||
| No | 17 (85.0%) | 11 (84.6%) | 1 |
| Yes | 3 (15.0%) | 2 (15.4%) | |
| CR/CRi at alloSCT | |||
| No | 2 (10.0%) | 3 (23.1%) | .64 |
| Yes | 17 (85.0%) | 10 (76.9%) | |
| Missing | 1 (5.0%) | 0 (0%) | |
| DRI | |||
| Low | 3 (15%) | 1 (7.7%) | .83 |
| Intermediate | 13 (65%) | 9 (69.2%) | |
| High | 3 (15%) | 2 (15.4%) | |
| NA | 1 (5%) | 1 (7.7%) | |
| Comutations | |||
| ASXL1 | |||
| No | 17 (85.0%) | 13 (100%) | .40 |
| Yes | 3 (15.0%) | 0 (0%) | |
| BCOR | |||
| No | 19 (95.0%) | 13 (100%) | 1 |
| Yes | 1 (5.0%) | 0 (0%) | |
| CEBPA | |||
| No | 17 (85.0%) | 9 (69.2%) | .52 |
| Yes | 3 (15.0%) | 4 (30.8%) | |
| CSF3R | |||
| No | 19 (95.0%) | 12 (92.3%) | 1 |
| Yes | 1 (5.0%) | 1 (7.7%) | |
| DNMT3A | |||
| No | 19 (95.0%) | 10 (76.9%) | .31 |
| Yes | 1 (5.0%) | 3 (23.1%) | |
| FLT3 | |||
| No | 14 (70.0%) | 4 (30.8%) | .06 |
| Yes | 6 (30.0%) | 9 (69.2%) | |
| IDH1 | |||
| No | 19 (95.0%) | 12 (92.3%) | 1 |
| Yes | 1 (5.0%) | 1 (7.7%) | |
| IDH2 | |||
| No | 19 (95.0%) | 13 (100%) | 1 |
| Yes | 1 (5.0%) | 0 (0%) | |
| GATA2 | |||
| No | 19 (95.0%) | 12 (92.3%) | 1 |
| Yes | 1 (5.0%) | 1 (7.7%) | |
| JAK2 | |||
| No | 19 (95.0%) | 12 (92.3%) | 1 |
| Yes | 1 (5.0%) | 1 (7.7%) | |
| KRAS | |||
| No | 19 (95.0%) | 13 (100%) | 1 |
| Yes | 1 (5.0%) | 0 (0%) | |
| NPM1 | |||
| No | 18 (90.0%) | 11 (84.6%) | 1 |
| Yes | 2 (10.0%) | 2 (15.4%) | |
| NRAS | |||
| No | 17 (85.0%) | 12 (92.3%) | .93 |
| Yes | 3 (15.0%) | 1 (7.7%) | |
| PHF6 | |||
| No | 19 (95.0%) | 13 (100%) | 1 |
| Yes | 1 (5.0%) | 0 (0%) | |
| PTPN11 | |||
| No | 19 (95.0%) | 11 (84.6%) | .69 |
| Yes | 1 (5.0%) | 2 (15.4%) | |
| RUNX1 | |||
| No | 18 (90.0%) | 9 (69.2%) | .29 |
| Yes | 2 (10.0%) | 4 (30.8%) | |
| SF3B1 | |||
| No | 20 (100%) | 11 (84.6%) | .29 |
| Yes | 0 (0%) | 2 (15.4%) | |
| SRSF2 | |||
| No | 19 (95.0%) | 13 (100%) | 1 |
| Yes | 1 (5.0%) | 0 (0%) | |
| TET2 | |||
| No | 18 (90.0%) | 12 (92.3%) | 1 |
| Yes | 2 (10.0%) | 1 (7.7%) | |
| TP53 | |||
| No | 19 (95.0%) | 13 (100%) | 1 |
| Yes | 1 (5.0%) | 0 (0%) | |
| ZRSR2 | |||
| No | 19 (95.0%) | 13 (100%) | 1 |
| Yes | 1 (5.0%) | 0 (0%) | |
| Transplantation characteristics and outcomes | |||
| HCT-CI ≥ 3 | |||
| No | 11 (55.0%) | 9 (69.2%) | .65 |
| Yes | 9 (45.0%) | 4 (30.8%) | |
| Conditioning intensity | |||
| Myeloablative | 12 (60.0%) | 8 (61.5%) | 1 |
| Reduced intensity | 7 (35.0%) | 5 (38.5%) | |
| Missing | 1 (5.0%) | 0 (0%) | |
| Conditioning | |||
| Bu/Cy | 4 (20.0%) | 1 (7.7%) | NA |
| Bu/Flu | 4 (20.0%) | 3 (23.1%) | |
| Bu/Flu/ATG | 1 (5.0%) | 0 (0%) | |
| Cy/Flu/thiotepa/TLI | 2 (10.0%) | 0 (0%) | |
| Cy/TBI | 2 (10.0%) | 2 (15.4%) | |
| Flu/Mel | 4 (20.0%) | 4 (30.8%) | |
| Flu/TBI | 2 (10.0%) | 1 (7.7%) | |
| Bu/Cy/ATG | 0 (0%) | 1 (7.7%) | |
| Flu/BCNU/Mel | 1 (5%) | 1 (7.7%) | |
| Graft source | |||
| Peripheral blood | 18 (90.0%) | 13 (100%) | 1 |
| Bone marrow | 1 (5.0%) | 0 (0%) | |
| Missing | 1 (5.0%) | 0 (0%) | |
| Donor type | |||
| MRD | 5 (25.0%) | 1 (7.7%) | .36 |
| MUD | 11 (55.0%) | 9 (69.2%) | |
| MMUD | 0 (0%) | 1 (7.7%) | |
| Haploidentical | 4 (20.0%) | 2 (15.4%) | |
| Major/bidirectional ABO mismatch | |||
| No | 15 (75.0%) | 10 (76.9%) | 1 |
| Yes | 4 (20.0%) | 3 (23.1%) | |
| Missing | 1 (5.0%) | 0 (0%) | |
| GVHD prophylaxis | |||
| CD34 selection | 1 (5.0%) | 0 (0%) | .16 |
| Tacrolimus + methotrexate (± ATG) | 13 (65%) | 9 (69.3%) | |
| Cyclosporine + methotrexate | 2 (10.0%) | 1 (7.7%) | |
| Tacrolimus + mycophenolate | 3 (15.0%) | 0 (0%) | |
| PT-Cy based | 0 (0%) | 3 (23.1%) | |
| None | 1 (5.0%) | 0 (0%) | |
| Grade 2-4 acute GVHD | |||
| No | 17 (85.0%) | 10 (76.9%) | .9 |
| Yes | 3 (15.0%) | 3 (23.1%) | |
| Grade 3-4 acute GVHD | |||
| No | 13 (65.0%) | 12 (92.3%) | .17 |
| Yes | 7 (35.0%) | 1 (7.7%) | |
| Moderate/severe chronic GVHD | |||
| No | 18 (90.0%) | 11 (84.6%) | 1 |
| Yes | 2 (10.0%) | 2 (15.4%) | |
ATG, anti-thymocyte globulin; BCNU, carmustine; Bu, busulfan; CRi, complete remission with incomplete count recovery; Cy, cyclophosphamide; Flu, fludarabine; GVHD, graft-versus-host disease; HCT-CI, hematopoietic stem cell transplant comorbidity index; max, maximum; Mel, melphalan; min, minimum; MRD, matched related donor; MMUD, mismatched unrelated donor; MUD, matched unrelated donor; PT, posttransplant; TBI, total body irradiation; TLI, total lymphoid irradiation; VAF, variant allele frequency.